Compositions, methods, and kits for eliciting an immune response
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/245
A61K-031/7105
C07K-014/005
A61K-045/06
A01N-063/00
A61K-039/00
출원번호
US-0748096
(2013-01-23)
등록번호
US-9011835
(2015-04-21)
발명자
/ 주소
Sampson, John H.
Mitchell, Duane A.
출원인 / 주소
Duke University
대리인 / 주소
Womble Carlyle Sandridge & Rice, LLP
인용정보
피인용 횟수 :
0인용 특허 :
24
초록
The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
대표청구항▼
1. A method for eliciting in a subject an immune response to a cancer cell that expresses a CMV antigen, the method comprising: selecting a subject in need of treatment related to the presence of the cancer cell; andadministering to the subject a composition comprising an effective amount of a T-lym
1. A method for eliciting in a subject an immune response to a cancer cell that expresses a CMV antigen, the method comprising: selecting a subject in need of treatment related to the presence of the cancer cell; andadministering to the subject a composition comprising an effective amount of a T-lymphocyte or an antigen presenting cell sensitized with at least one CMV antigen, wherein the effective amount of the T-lymphocyte or the antigen presenting cell is sufficient to elicit the immune response to the cancer cell that expresses the CMV antigen. 2. The method of claim 1, wherein the at least one CMV antigen is a polypeptide, or an immunogenic fragment thereof, selected from the group consisting of: a capsid polypeptide, a tegument polypeptide, and a envelope polypeptide. 3. The method of claim 1, wherein the at least one CMV antigen is a polypeptide, or an immunogenic fragment thereof, selected from the group consisting of: phosphoprotein unique long 83 (ppUL83; a/k/a pp65), glycoprotein UL55 (gpUL55; a/k/a gB), UL123 immediate early 1 (IE1) protein, UL122 IE2 protein, UL111A (a/k/a mtrII), US28, ppUL32, ppUL65, ppUL80a, ppUL82, ppUL98a, ppUL99, gpUL4 (a/k/a gp48), gpUL16, gpUL18 (a/k/a MHC), gpUL75 (a/k/a gH), gpUL100, gpUL110 (a/k/a gM), gpUL115 (a/k/a gL), pUL46, pUL48, pUL56, pUL86 (a/k/a MCP), glycoprotein unique short 10 (gpUS10), gpUS11, glycoprotein complex II (gcII), gp65, and gp93. 4. The method of claim 1, wherein the at least one CMV antigen comprises an amino acid sequence as set forth in SEQ ID NO:109. 5. The method of claim 1, wherein the composition further comprises at least one adjuvant. 6. The method of claim 5, wherein the adjuvant is incomplete Freund's adjuvant (Montanide ISA 51) or Corynebacterium granulosum P40. 7. The method of claim 1, wherein the composition further comprises a cytokine. 8. The method of claim 7, wherein the cytokine is selected from the group consisting of: GM-CSF, G-CSF, IL-2, IL-4, IL-7, IL-12, IL-15, IL-21, TNF-α, and M-CSF. 9. The method of claim 1 further comprising of detecting the expression of the CMV antigen by the cancer cell in the subject. 10. A method for eliciting in a subject an immune response to a cancer cell that expresses a CMV antigen, the method comprising: selecting a subject in need of treatment related to the presence of the cancer cell, wherein the cancer cell is a glioblastoma multiforme (GBM) cancer cell; andadministering to the subject a composition comprising an effective amount of an antigen presenting cell sensitized with at least one CMV antigen, wherein the effective amount of the antigen presenting cell is sufficient to elicit the immune response to the cancer cell that expresses the CMV antigen, wherein the antigen presenting cell is a dendritic cell.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (24)
Bigner, Darell D.; Sampson, John H.; Ashley, David M.; Hale, Laura P., Allogeneic cellular vaccine.
Lyon Jeffery A. (Silver Spring MD) Chulay Jeffrey L. (Washington DC) Thomas Alan W. (Silver Spring MD) Howard Russell J. (Los Altos Hills CA) Weber James L. (Marshfield WI), Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents.
Thomas Dag Horn ; Sandra Marchese Johnson, Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction.
Taylor, Ronald; Nardin, Alessandra; Sutherland, William M.; Sokoloff, Mitchell H.; Chung, Leland, Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies.
Eisenbach,Lea; Carmon,Lior; Tirosh,Boaz; Bar Haim,Erez; Paz,Adrian; Fridkin,Matityahu; Fitzer Attas,Cheryl, Tumor associated antigen peptides and use of same as anti-tumor vaccines.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.